Comparative Pharmacology
Head-to-head clinical analysis: HECTOROL versus ZEMPLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HECTOROL versus ZEMPLAR.
HECTOROL vs ZEMPLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
Vitamin D receptor agonist; binds to vitamin D receptors, regulating gene expression of calcium-binding proteins and cellular proliferation/differentiation.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
0.04-0.1 mcg/kg IV three times weekly; titrate to serum calcium. Oral: 1-2 mcg daily or 0.5-1 mcg three times weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Terminal elimination half-life is 5–7 hours in healthy subjects; prolonged to 14–21 hours in patients with chronic kidney disease stage 5 on hemodialysis, reflecting reduced clearance.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Primarily hepatobiliary (74% of absorbed dose recovered in feces as parent drug and metabolites); renal excretion accounts for approximately 16% (primarily as metabolites).
Category C
Category C
Vitamin D Analog
Vitamin D Analog